Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) posted its earnings results on Thursday. The company reported ($0.01) EPS for the quarter, Zacks reports.
Appili Therapeutics Price Performance
APLIF stock traded down $0.00 during trading on Thursday, reaching $0.01. 10,000 shares of the company were exchanged, compared to its average volume of 51,217. The company has a market capitalization of $1.85 million, a price-to-earnings ratio of -0.72 and a beta of -0.28. The company has a 50-day moving average of $0.02 and a two-hundred day moving average of $0.02. Appili Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.03.
Appili Therapeutics Company Profile
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
See Also
- Five stocks we like better than Appili Therapeutics
- USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.
- My Epstein Story
- When to buy gold (mathematically)
- What central banks are doing with gold right now
- Think You Missed Silver? You’re Wrong. Here’s Why.
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
